Zhang L.,Chinese PLA General Hospital |
Li P.,Chinese PLA General Hospital |
Xing C.-Y.,Nanjing Medical University |
Zhao J.-Y.,Dalian Medical University |
And 24 more authors.
American Journal of Kidney Diseases | Year: 2014
Background Abelmoschus manihot, a single medicament of traditional Chinese medicine, has been widely used to treat kidney disease. This is the first randomized controlled clinical trial to assess its efficacy and safety in patients with primary glomerular disease. Study Design Prospective, open-label, multicenter, randomized, controlled, clinical trial. Setting & Participants From May 2010 to October 2011, a total of 417 patients with biopsy-proven primary glomerular disease from 26 hospitals participated in the study. Interventions A manihot in the form of a huangkui capsule, 2.5 g, 3 times per day; losartan potassium, 50 mg/d; or combined treatment, a huangkui capsule at 2.5 g 3 times per day, was combined with losartan potassium, 50 mg/d. The duration of intervention was 24 weeks. Outcomes & Measurements The primary outcome was change in 24-hour proteinuria from baseline after treatment. Change in estimated glomerular filtration rate (eGFR) from baseline after treatment was a secondary outcome. The 24-hour proteinuria was measured every 4 weeks and eGFR was measured at 0, 4, 12, and 24 weeks. Results Mean baseline urine protein excretion was 1,045, 1,084, and 1,073 mg/d in the A manihot, losartan, and combined groups, respectively, and mean eGFR was 108, 106, and 106 mL/min/1.73 m2, respectively. After 24 weeks of treatment, mean changes in proteinuria were protein excretion of -508, -376, and -545 mg/d, respectively (P = 0.003 for A manihot vs losartan and P < 0.001 for the combined treatment vs losartan). Mean eGFR did not change significantly. The incidence of adverse reactions was not different among the 3 groups (P > 0.05), and there were no severe adverse events in any group. Limitations Results cannot be generalized to those with nephrotic syndrome or reduced eGFR. Conclusions A manihot is a promising therapy for patients with primary kidney disease (chronic kidney disease stages 1-2) with moderate proteinuria. © 2014 by the National Kidney Foundation, Inc.
Chen J.,Jinan General Hospital of PLA |
Zhu C.,Jinan General Hospital of PLA |
Zhu M.,Shanghai University |
Geng M.,Jinan General Hospital of PLA |
And 3 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015
Background: The expression and clinical significance of TIP30 and p53 in laryngeal squamous cell carcinoma (LSCC) have not been investigated. Method: We determined immunohistochemically the expression of TIP30 and p53 in surgical specimens from 105 patients with LSCC. Survivals were estimated using the Kaplan-Meier method. Results: TIP30 protein expression in LSCC patients was significantly less in tumor tissues than that of adjacent normal tissues (46.7% vs. 79.0%), while p53 protein expression was significantly increased in LSCC (15.2% vs. 63.8%) compared with adjacent normal tissues. The TIP30 expression levels were also significantly correlated with tumor stage, differentiation, and the presence of lymph nodes. The expression of TIP30 was significantly negatively correlated with that of p53 (r = -0.249, P = 0.010). LSCC patients with lower expression level of TIP30 had a significantly higher recurrence and worse overall survival than those with elevated TIP30 expression (P = 0.014 and P = 0.040, respectively). Furthermore, multivariable analysis found that patients with high expression of TIP30 had a greater than approximately 2.2-fold increased risk for death overall or recurrence than those with low expression of TIP30, supporting that down-regulation of TIP30 expression in tumors may involve in development and progression and predict poor prognosis of patients with LSCC. Conclusion: Our results may suggest that down-expression of TIP30 is closely related to carcinogenesis, progression, biological behavior, and prognosis of LSCC. © 2015, E-Century Publishing Corporation. All rights reserved.
Yu S.,Fudan University |
Yu S.,Tongji University |
Zhang R.,Fudan University |
Zhu C.,Jinan General Hospital of PLA |
And 3 more authors.
International Journal of Molecular Sciences | Year: 2013
MicroRNA-143 (miR-143) was found to be downregulated in allergic rhinitis, and bioinformatics analysis predicted that IL-13Rα was a target gene of miR-143. To understand the molecular mechanisms of miR-143 involved in the pathogenesis of allergic inflammation, recombinant miR-143 plasmid vectors were constructed, and human mast cell-1(HMC-1) cells which play a central role in the allergic response were used for study. The plasmids were transfected into HMC-1 cells using a lentiviral vector. Expression of IL-13Rα mRNA was then detected by reverse transcriptase polymerase chain reaction (RT-PCR) and Western Blotting. The miR-143 lentiviral vector was successfully stably transfected in HMC-1 cells for target gene expression. Compared to the control, the target gene IL-13Rα was less expressed in HMC-1 transfected with miR-143 as determined by RT-PCR and Western Blotting (p < 0.05); this difference in expression was statistically significant and the inhibition efficiency was 71%. It indicates that miR-143 directly targets IL-13Rα and suppresses IL-13Rα expression in HMC-1 cells. Therefore, miR-143 may be associated with allergic reaction in human mast cells. © 2013 by the authors; licensee MDPI, Basel, Switzerland.
Zhang A.,Jinan General Hospital of PLA |
Liu Y.,Jinan General Hospital of PLA |
Shen Y.,Jinan General Hospital of PLA |
Xu Y.,Jinan General Hospital of PLA |
Li X.,Jinan General Hospital of PLA
Urology | Year: 2011
Objectives: To explore the mechanism of miR-21 involved in the development of renal cell carcinoma. Methods: Cell proliferation and apoptosis were measured after repression of miR-21 expression by antisense oligonucleotides. miR-21 targets were scanned using target prediction programs. After reduction of miR-21, Fas ligand and metalloproteinase inhibitor 3 (TIMP3) expression and luciferase activity were detected by Western blot and luciferase reporter assay. The effect of TIMP3 on miR-21-induced cell survival was determined by transfection with TIMP3 lacking 3′ untranslated region and miR-21. Results: The reduction of miR-21 by antisense oligonucleotides inhibited cell proliferation and induced cell apoptosis by activation of caspase pathway in renal cell carcinoma cells. Moreover, bioinformatics analysis revealed that miR-21 has the potential to regulate multiple apoptosis-related genes. The reduction of miR-21 inhibited Fas ligand and TIMP3 expression by targeting the binding site within the 3′ untranslated region. Finally, the introduction of TIMP3 cDNA without 3′ untranslated region abrogated miR-21-induced cell survival. Conclusions: Together, these findings indicate that miR-21 plays a key role in regulating cell apoptosis by targeting multiple genes in renal cell carcinoma. © 2011 Elsevier Inc.